Inhibitors of hepatitis C - A review of the recent patent literature

IDrugs

Volumn 5, Issue 2, 2002, Pages 154-158

  Zhang, Xiaojun ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; ALPHA INTERFERON; AMIDE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BORONIC ACID DERIVATIVE; DEOXYCYTIDINE TRIPHOSPHATE; HETEROCYCLIC COMPOUND; INOSINATE DEHYDROGENASE INHIBITOR; MACROCYCLIC COMPOUND; MERIMEPODIB; NUCLEOSIDE ANALOG; RHODANINE; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; RNA HELICASE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SYNTHETIC PEPTIDE; TRIPEPTIDE; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS PROTEIN; VP 50406;

CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRUG TARGETING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0000885084     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Cohen J: The scientific challenge of hepatitis C. Science (1999) 285:26-30.
2. Myles DC: Recent advances in the discovery of small molecule therapies for HCV. Curr Opin Drug Disc Dev (2001) 4:411-416. A review of small molecule inhibitors of HCV.
3. Zein NN: Experimental and emerging therapies for chronic hepatitis C virus infection. Expert Opin Invest Drugs (2001) 10:1457-1469. An excellent review of experimental and emerging therapies for HCV infection.
4. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 244:359-362.
5. Yanagi M, St Claire M, Emerson SU, Purcell RH, Bukh J: In vivo analysis of the 3′ untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Proc Natl Acad Sci USA (1999) 96:2291-2295.
6. Houghton M: Strategies and prospects for vaccination against the hepatitis C viruses. Curr Top Microbiol Immunol (2000) 242:327-339.
7. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai M-Y, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ: Peginterferon alfa-2a in patients with chronic hepatitis C. New Engl J Med (2000) 343:1666-1672.
8. Markland W, McQuaid TJ, Jain J, Kwong AD: Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: A comparison with ribavirin and demonstration of antiviral additivity with α-interferon. Antimicrob Agents Chemother (2000) 44:859-866.
9. Lohmann V, Korner F, Koch JO, Herian U, Theilmann L, Bartenschlager R: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 285:110-113. This paper describes the first stable cell-based assay for HCV.
10. Kolykhalov A, Mihalik K, Feinstone S, Rice C: Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J Virol (2000) 74:2046-2051.
11. Love R, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, Margosiak S, Dagostino E, Hostomska Z: The conformation of hepatitis C virus NS3 proteinase with and without NS4A: A structural basis for the activation of the enzyme by its cofactor. Clin Diag Virol (1998) 10:151-156.
12. Love R, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, Hostomska Z: The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell (1996) 87:331-342.
13. Pessi A: A personal account of the role of peptide research in drug discovery: The case of hepatitis C. J Peptide Sci (2001) 7:2-14. A review of the impact of peptide research on the development of HCV-NS3 inhibitors.
14. Edwards PD, Bernstein PR: Synthetic inhibitors of elastase. Med Res Rev (1994) 14:127-194.
15. Jagannathan S, Forsyth TP, Kettner CA: Synthesis of boronic acid analogues of α-amino acids by introducing side chains as electrophiles. J Org Chem (2001) 66:6375-6380.
16. Kim JL, Morgenstern KA, Griffith JP, Dwyer MD, Thomson JA, Murcko MA, Lin C, Caron PR: Crystal structure of hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide. Structure (1998) 6:89-100.
17. Phoon CW, Ng PY, Ting AE, Yeo SL, Sim MM: Biological evaluation of hepatitis C virus helicase inhibitors. Bioorg Med Chem Lett (2001) 11:1647-1650.
18. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM: Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science (1997) 277:570-574.
19. Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R, Rey FA: Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA (1999) 96:13034-13039
20. Boehringer Ingelheim (Canada) Ltd (Llinas-Brunet M, Bailey MD, Cameron D, Ghiro E, Goudreau N, Poupart M-A, Rancourt J, Tsantrizos YS): Hepatitis C inhibitor peptides. WO-00009558 (2000).
21. Boehringer Ingelheim (Canada) Ltd (Tsantrizos YS, Cameron DR, Faucher A-M, Ghiro E, Goudreau N, Halmos T, Llinas-Brunet M): Macrocyclic peptides active against the hepatitis C virus. WO-00059929 (2000).
22. Schering Corp (Chen KX, Arasappan A, Venkatraman S, Parekh TN, Gu H, Njoroge FG, Girijavallabhan VM, Ganguly A, Saksena A, Jao E, Yao NH, Prongay AJ, Madison VS, Vibulbhan B): Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising n-cyclic p2 moieties. WO-00177113 (2001).
23. DuPont Pharmaceuticals Co (Han W): Alpha-keto amide inhibitors of hepatitis C virus NS3 protease. WO-00140262 (2001).
24. Vertex Pharmaceuticals Inc (Perni R, Court J, O'Malley E, Bhisetti GR): Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. WO-00174768 (2001).
25. Schering Corp (Zhang R): Azapeptides useful in the treatment of hepatitis C. WO-00158929 (2001).
26. DuPont Pharmaceuticals Co (Priestly ES, Decicco CP): Lactam inhibitors of hepatitis C virus NS3 protease. WO-00107407 (2001).
27. DuPont Pharmaceuticals Co (Zhang X, Han W): Inhibitors of hepatitis C virus NS3 protease. WO-00164678 (2001).
28. Vertex Pharmaceuticals Inc (Hale M, Maltais F, Baker C, Janetka J, Moon YC, Saunders J): Inhibitors of viral helcase (sic). WO-00107027 (2001).
29. Viropharma Inc (Diana GD, Bailey TR): Compounds, compositions and methods for treatment of hepatitis C. US-05633388 (1997).
30. Merck & Co Inc (Darke PL, Jacobs AR, Kuo LC): Hepatitis C virus replication inhibitors. WO-00116379 (2001).
31. Istituto di Ricerche di Biologia Molecolare (Altamura S, Tomei L, Koch U, Neuner PJS, Summa V): Diketoacid derivatives as inhibitors of viral polymerases. WO-00006529 (2000).
32. Tularik Inc (Jaen JC, Piper DE, Powers JP, Walker NPC, Li Y): NS5B HCV polymerase inhibitors. WO-00177091 (2001).
33. Biochem Pharma Inc (Ismaili HMA, Cheng Y-X, Lavallée J-F, Siddiqui A, Storer R): Method for the treatment or prevention of flavivirus infections using nucleoside analogues. WO-00160315 (2001).
34. Japan Tobacco Inc (Hashimoto H, Mizutani K, Yoshida A): Fused-ring compounds and use thereof as drugs. WO-00147883 (2001)